MYFEMBREE is a combination therapy indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and moderate to severe pain associated with endometriosis, providing therapeutic benefits by regulating hormonal imbalances.

Therapeutic Effect of MYFEMBREE in Managing Endometriosis and Uterine Leiomyomas

MYFEMBREE is a combination oral medication composed of relugolix, estradiol, and norethindrone acetate, aimed at managing specific gynecological conditions in premenopausal women. It is indicated for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and moderate to severe pain linked with endometriosis. The primary therapeutic effect of MYFEMBREE stems from its ability to regulate hormonal pathways that contribute to abnormal bleeding and pain in these conditions. Relugolix, a GnRH receptor antagonist, suppresses gonadotropin secretion, reducing estrogen production, while estradiol and norethindrone acetate help stabilize the endometrial lining and menstrual cycle, ultimately alleviating symptoms. MYFEMBREE's use is limited to a maximum of 24 months due to concerns about long-term bone density reduction.